Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

• Status: Unknown status
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• All patients diagnosed with Behcet's disease on any DMARDs

Exclusion Criteria:

• Patients with critical conditions

• Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.